Investors need to know if Eli Lilly will face the identical pricing pressure on its ...
Eli Lilly reported on Thursday Second quarter results and revenue exceeded all expectations, raising full-year ...
All cans of Eli Lilly's The hugely popular weight reduction injection Zepbound and the diabetes ...
Eli LillyThe weight reduction drug Zepbound showed advantages in patients with common kind of heart ...
The lucrative weight-loss drug market won't remain a duopoly eternally. With billions at stake, that ...
Good morning! Eli Lilly, Novo Nordisk and other pharmaceutical corporations presented encouraging data on weight-loss ...
Every weekday, CNBC Investing Club with Jim Cramer publishes the Homestretch — an actionable afternoon ...
The Food and Drug Administration approved on Tuesday Eli LillyThe Alzheimer's drug Donanemab expands the ...
Eli Lilly announced on Friday that it has applied for U.S. approval of its weight-loss ...
The rapidly increasing demand for a category of weight reduction and diabetes drugs has Eli ...